W R Crom
Overview
Explore the profile of W R Crom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnaout M, Radomski K, Srivastava D, Tong X, Belt J, Raimondi S, et al.
Leukemia
. 2000 Oct;
14(10):1736-42.
PMID: 11021748
The purpose of this study was to assess the feasibility and efficacy of a treatment regimen for pediatric acute myelogenous leukemia (AML) that uses four rotating drug pairs and adjusts...
2.
Evans W, Relling M, Rodman J, Crom W, Boyett J, Pui C
N Engl J Med
. 1998 Feb;
338(8):499-505.
PMID: 9468466
Background: The rate of clearance of antileukemic agents differs by a factor of 3 to 10 among children with acute lymphoblastic leukemia. We hypothesized that the outcome of treatment would...
3.
Zamboni W, Houghton P, Johnson R, Hulstein J, Crom W, Cheshire P, et al.
J Pharmacol Exp Ther
. 1998 Jan;
284(1):89-94.
PMID: 9435165
Topotecan is primarily eliminated by the kidneys, with 60 to 70% of the dose recovered as topotecan total in the urine. To elucidate the mechanisms of topotecan renal clearance, we...
4.
Pappo A, Bowman L, Furman W, Rao B, Kun L, Jenkins J, et al.
J Pediatr Hematol Oncol
. 1997 Nov;
19(5):438-42.
PMID: 9329466
Purpose: The outcome for children with advanced-stage rhabdomyosarcoma remains poor with contemporary treatment regimens. Evaluation of new drugs is important to improve clinical outcome. Because methotrexate has shown promising activity...
5.
Stewart C, Zamboni W, Crom W, Houghton P
Cancer Chemother Pharmacol
. 1997 Jan;
40(3):259-65.
PMID: 9219511
The present study was conducted to quantitate the disposition of irinotecan lactone and its active metabolite SN-38 lactone in mice following oral and intravenous administration, and to evaluate the systemic...
6.
Kearns G, Crom W, Karlson Jr K, Mallory Jr G, Evans W
Clin Pharmacol Ther
. 1996 May;
59(5):529-40.
PMID: 8646824
The plasma disposition of three model substrates (lorazepam, indocyanine green, and antipyrine) and the formation clearance of antipyrine metabolites (3-hydroxymethylantipyrine, norantipyrine, and 4-hydroxyantipyrine) were evaluated in 15 subjects with mild...
7.
Stewart C, Zamboni W, Crom W, Gajjar A, Heideman R, Furman W, et al.
Invest New Drugs
. 1996 Jan;
14(1):37-47.
PMID: 8880392
Topotecan, irinotecan, and 9-aminocamptothecin (9-AC) are analogs of the plant alkaloid 20(S)-camptothecin (CMT), the prototypical DNA topoisomerase I interactive agent. These agents interact with the topoisomerase I-DNA complex and prevent...
8.
Baker S, Heideman R, Crom W, Kuttesch J, Gajjar A, Stewart C
Cancer Chemother Pharmacol
. 1996 Jan;
37(3):195-202.
PMID: 8529278
The purpose of this study was to describe the cerebrospinal fluid (CSF) penetration of topotecan in humans, to generate a pharmacokinetic model to simultaneously describe topotecan lactone and total concentrations...
9.
Murry D, Crom W, Reddick W, Bhargava R, Evans W
Drug Metab Dispos
. 1995 Oct;
23(10):1110-6.
PMID: 8654200
Many drugs eliminated by the liver exhibit age-related differences in systemic clearance, necessitating different dosage requirements in children and adults. However, the physiological basis for these age-related changes is not...
10.
Crom W
Environ Health Perspect
. 1994 Dec;
102 Suppl 11:111-7.
PMID: 7737035
Pharmacokinetic studies have made many significant contributions to rational therapeutics in children. Pharmacokinetic data have helped distinguish between differences in drug disposition and drug sensitivity in children as compared to...